Malignancy risk and screening

Alexandra Ladouceur; Ann E. Clarke; Rosalind Ramsey-Goldman; Caroline Gordon; Sasha Bernatsky

doi:10.1016/B978-0-12-820583-9.00007-5

Malignancy risk and screening

Alexandra Ladouceur, Ann E. Clarke, Rosalind Ramsey-Goldman, Caroline Gordon, Sasha Bernatsky

Medicine, Rheumatology Division

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Several studies have provided persuasive evidence that patients with systemic lupus erythematosus (SLE) have an altered cancer risk profile when compared with the general population. SLE patients display a higher risk of certain malignancies (e.g., hematologic, lung), whereas they seem at lower risk of others (e.g., breast cancer). This altered risk is probably explained by multiple factors, including immunosuppressant drugs, susceptibility to certain viruses, genetic factors, clinical factors, race/ethnicity, immune dysregulation, cytokines, and hormonal factors.

Original language	English (US)
Title of host publication	Lahita’s Systemic Lupus Erythematosus
Publisher	Elsevier
Pages	583-598
Number of pages	16
ISBN (Electronic)	9780128205839
DOIs	https://doi.org/10.1016/B978-0-12-820583-9.00007-5
State	Published - Jan 1 2021

Keywords

Cancer
Epidemiology
Malignancy
Screening
Systemic lupus erythematosus (SLE)

ASJC Scopus subject areas

General Medicine
General Immunology and Microbiology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-12-820583-9.00007-5

Cite this

@inbook{7f41293bf52445248b40f59851e9615f,

title = "Malignancy risk and screening",

abstract = "Several studies have provided persuasive evidence that patients with systemic lupus erythematosus (SLE) have an altered cancer risk profile when compared with the general population. SLE patients display a higher risk of certain malignancies (e.g., hematologic, lung), whereas they seem at lower risk of others (e.g., breast cancer). This altered risk is probably explained by multiple factors, including immunosuppressant drugs, susceptibility to certain viruses, genetic factors, clinical factors, race/ethnicity, immune dysregulation, cytokines, and hormonal factors.",

keywords = "Cancer, Epidemiology, Malignancy, Screening, Systemic lupus erythematosus (SLE)",

author = "Alexandra Ladouceur and Clarke, {Ann E.} and Rosalind Ramsey-Goldman and Caroline Gordon and Sasha Bernatsky",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-820583-9.00007-5",

language = "English (US)",

pages = "583--598",

booktitle = "Lahita{\textquoteright}s Systemic Lupus Erythematosus",

publisher = "Elsevier",

}

TY - CHAP

T1 - Malignancy risk and screening

AU - Ladouceur, Alexandra

AU - Clarke, Ann E.

AU - Ramsey-Goldman, Rosalind

AU - Gordon, Caroline

AU - Bernatsky, Sasha

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Several studies have provided persuasive evidence that patients with systemic lupus erythematosus (SLE) have an altered cancer risk profile when compared with the general population. SLE patients display a higher risk of certain malignancies (e.g., hematologic, lung), whereas they seem at lower risk of others (e.g., breast cancer). This altered risk is probably explained by multiple factors, including immunosuppressant drugs, susceptibility to certain viruses, genetic factors, clinical factors, race/ethnicity, immune dysregulation, cytokines, and hormonal factors.

AB - Several studies have provided persuasive evidence that patients with systemic lupus erythematosus (SLE) have an altered cancer risk profile when compared with the general population. SLE patients display a higher risk of certain malignancies (e.g., hematologic, lung), whereas they seem at lower risk of others (e.g., breast cancer). This altered risk is probably explained by multiple factors, including immunosuppressant drugs, susceptibility to certain viruses, genetic factors, clinical factors, race/ethnicity, immune dysregulation, cytokines, and hormonal factors.

KW - Cancer

KW - Epidemiology

KW - Malignancy

KW - Screening

KW - Systemic lupus erythematosus (SLE)

UR - http://www.scopus.com/inward/record.url?scp=85127702189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127702189&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-820583-9.00007-5

DO - 10.1016/B978-0-12-820583-9.00007-5

M3 - Chapter

AN - SCOPUS:85127702189

SP - 583

EP - 598

BT - Lahita’s Systemic Lupus Erythematosus

PB - Elsevier

ER -

Malignancy risk and screening

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this